Search

Reaction of a series of linked diimidazolium dibromide salts with one-half equivalent of [Rh(μ-OAc)(COD)]2under reflux conditions generates a series of carbene-anchored/pendent-imidazolium complexes, [RhBr(COD)(RC(H)-η1-Ceth)][Br] (MeC(H)-η1-Ceth= ethylene[(N-methyl)imidazolium][(N-methyl)imidazole-2-ylidene] and tBuC(H)-η1-Ceth= ethylene[(N-tert-butyl)imidazolium][(N-tert-butyl)imidazole-2-ylidene]) viadeprotonation of one end of the diimidazolium salt and coordination of the resulting carbene to Rh. Reaction of these complexes with carbon monoxide or the appropriate diphosphine yields either [RhBr(CO)2(RC(H)-η1-Ceth)][Br] (R = Me, tBu) or [RhBr(P∩P)(MeC(H)-η1-Ceth)][Br] (P∩P = Ph2PCH2PPh2, Ph2PCH2CH2PPh2, Et2PCH2PEt2), respectively. The resulting diphosphine complexes readily decompose in solution. A series of palladium complexes [PdI3-n(PR3)n(L)][I]n(n = 1,2) and [PdI(P∩P)(L)][I]2(L = tBuC(H)-η1-Cmeth, tBuC(H)-η1-Ceth; tBuC(H)-η1-Cmeth= methylene[(N-tert-butyl)imidazolium][(N-tert-butyl)imidazole-2-ylidene]), containing the linked NHC-imidazolium moiety, have also been prepared by reacting the triiodo complexes, [PdI3(tBuC(H)-η1-Cmeth)] and [PdI3(tBuC(H)-η1-Ceth)] with several mono- and diphosphines. Attempts to generate mixed Rh/Pd complexes using Pd(OAc)2to deprotonate the pendent arm of several of the above carbene-anchored/pendent-imidazolium complexes of Rh have proven unsuccessful. However, a targeted di-NHC-bridged heterobimetallic complex [PdI2(PEt3)(μ-tBuCCmeth)RhI(COD)] (tBuCCmeth= 1,1′-methylene-3,3′-di-tert-butyldiimidazol-2,2′-diylidene) can be generated by deprotonation of the imidazolium group in [PdI2(PEt3)(tBuC(H)-η1-Cmeth)][I] using half an equivalent of [Rh(μ-OAc)(COD)]2. The X-ray structure determination of this Pd/Rh complex confirms the dicarbene-bridged formulation and shows a metal-metal separation of approximately 6.2 Å. Reaction of this Rh/Pd complex with CO yields the corresponding dicarbonyl product [PdI2(PEt3)(μ-tBuCCmeth)RhI(CO)2] viareplacement of the COD ligand. The related dicarbene-bridged Ir/Rh complex [IrBr(COD)(μ-tBuCCmeth)RhBr(COD)] can be generated by reaction of [IrBr(COD)(tBuC(H)-η1-Cmeth)][Br] with [Rh(μ-OAc)(COD)]2, while the Pd/Ir complexes [PdI2(PR3)(μ-tBuCCmeth)IrI(COD)] (PR3= PPh3, PMe2Ph) can be generated by reaction of the monometallic [PdI2(PR3)(tBuC(H)-η1-Cmeth)][I] species with K[N(SiMe3)2] in the presence of [Ir(μ-Cl)(COD)]2. The carbonyl analogues, [PdI2(PR3)(μ-tBuCCmeth)IrI(CO)2], can be generated viaa gentle purge of CO gas. These di-NHC-bridged heterobimetallic species represent some of the first examples of this class and are the first involving palladium. [ABSTRACT FROM AUTHOR]

Aims: Recent updates of international treatment guidelines for heart failure with reduced ejection fraction (HFrEF) differ regarding the use of angiotensin receptor neprilysin inhibitor (ARNI) as first‐line treatment. The American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) 2022 guidelines gives ARNI a Class IA recommendation for HFrEF patients while the European Society of Cardiology's guidelines are less clear when ARNI could be considered as first line treatment option in de novo patients. This study aimed to model the clinical and budgetary outcomes of implementing these guidelines, comparing conservative ARNI prescription patterns with less conservative in Sweden and in the United Kingdom. Methods and results: A health economic model was developed to compare different treatment patterns for HFrEF. Incident cohorts were included on an annual basis and followed over 10 years. The model included treatment specific all‐cause mortality and hospitalization rates, as well as drug acquisition, monitoring, and hospitalization costs. Increasing the use of ARNI could lead to about 7000–12 300 life years gained and 2600–4600 hospitalizations prevented in Sweden. These health benefits come with an additional cost of 112–195 million euros. Similar results were estimated for the United Kingdom, albeit on a larger population. Conclusions: Increasing the proportion of patients receiving ARNI instead of angiotensin converting enzyme inhibitors as first‐line treatment of HFrEF will lead to a considerable number of additional life years gained and prevented hospitalizations but with additional cost in terms of health care expenditure in Sweden and in the United Kingdom. [ABSTRACT FROM AUTHOR]

Aims There are few data on the feasibility of population screening for paroxysmal atrial fibrillation (AF) using hand-held electrocardiogram (ECG) devices outside a specialist setting or in people over the age of 75. We investigated the feasibility of screening when conducted without face-to-face contact ('remote') or via in-person appointments in primary care and explored impact of age on screening outcomes. Methods and results People aged ≥65 years from 13 general practices in England participated in screening during 2019–20. This involved attending a practice nurse appointment (10 practices) or receiving an ECG device by post (three practices). Participants were asked to use a hand-held ECG for 1–4 weeks. Screening outcomes included uptake, quality of ECGs, AF detection rates, and uptake of anticoagulation if AF was detected. Screening was carried out by 2141 (87.5%) of people invited to practice nurse-led screening and by 288 (90.0%) invited to remote screening. At least 56 interpretable ECGs were provided by 98.0% of participants who participated for 3 weeks, with no significant differences by setting or age, except people aged 85 or over (91.1%). Overall, 2.6% (64/2429) screened participants had AF, with detection rising with age (9.2% in people aged 85 or over). A total of 53/64 (82.8%) people with AF commenced anticoagulation. Uptake of anticoagulation did not vary by age. Conclusion Population screening for paroxysmal AF is feasible in general practice and without face-to-face contact for all ages over 64 years, including people aged 85 and over. [ABSTRACT FROM AUTHOR]

Although the development of therapies and tools for the improved management of heart failure (HF) continues apace, day‐to‐day management in clinical practice is often far from ideal. A Cardiovascular Round Table workshop was convened by the European Society of Cardiology (ESC) to identify barriers to the optimal implementation of therapies and guidelines and to consider mitigation strategies to improve patient outcomes in the future. Key challenges identified included the complexity of HF itself and its treatment, financial constraints and the perception of HF treatments as costly, failure to meet the needs of patients, suboptimal outpatient management, and the fragmented nature of healthcare systems. It was discussed that ongoing initiatives may help to address some of these barriers, such as changes incorporated into the 2021 ESC HF guideline, ESC Heart Failure Association quality indicators, quality improvement registries (e.g. EuroHeart), new ESC guidelines for patients, and the universal definition of HF. Additional priority action points discussed to promote further improvements included revised definitions of HF 'phenotypes' based on trial data, the development of implementation strategies, improved affordability, greater regulator/payer involvement, increased patient education, further development of patient‐reported outcomes, better incorporation of guidelines into primary care systems, and targeted education for primary care practitioners. Finally, it was concluded that overarching changes are needed to improve current HF care models, such as the development of a standardized pathway, with a common adaptable digital backbone, decision‐making support, and data integration, to ensure that the model 'learns' as the management of HF continues to evolve. [ABSTRACT FROM AUTHOR]

The article discusses the highlights of the 18th Annual Autumn Meeting of the British Society for Heart Failure (BSH) which was held on November 26-27, 2015 at the Queen Elizabeth II Conference Centre Westminster in London, England. The meeting was entitled "Pathways of care." It presents the various presentations that highlighted how using the national and local data can support "transforming outcomes for patients." Professor Martin Cowie provided a synopsis of the SERVE HF Trial.

Big data is central to new developments in global clinical science aiming to improve the lives of patients. Technological advances have led to the routine use of structured electronic healthcare records with the potential to address key gaps in clinical evidence. The covid-19 pandemic has demonstrated the potential of big data and related analytics, but also important pitfalls. Verification, validation, and data privacy, as well as the social mandate to undertake research are key challenges. The European Society of Cardiology and the BigData@Heart consortium have brought together a range of international stakeholders, including patient representatives, clinicians, scientists, regulators, journal editors and industry. We propose the CODE-EHR Minimum Standards Framework as a means to improve the design of studies, enhance transparency and develop a roadmap towards more robust and effective utilisation of healthcare data for research purposes. [ABSTRACT FROM AUTHOR]

The article discusses that Editors of the European and the American Journals of Cardiovascular Nursing discussed the dos and the don'ts when writing an article.

Aims Right ventricular (RV) strain is a known predictor of outcomes in various heart and lung pathologies but has been considered too technically challenging for routine use in critical care. We examined whether RV strain acquired from the subcostal view, frequently more accessible in the critically ill, is an alternative to conventionally derived RV strain in intensive care. Methods and results RV strain data were acquired from apical and subcostal views on transthoracic echocardiography (TTE) in 94 patients (35% female), mean age 50.5 ± 15.2 years, venovenous extracorporeal membrane oxygenation (VVECMO) (44%). RV strain values from the apical (mean ± standard deviation; –20.4 ± 6.7) and subcostal views (–21.1 ± 7) were highly correlated (Pearson's r –0.89, P < 0.001). RV subcostal strain correlated moderately well with other echocardiography parameters including tricuspid annular plane systolic excursion (r –0.44, P < 0.001), RV systolic velocity (rho = –0.51, P < 0.001), fractional area change (r –0.66, P < 0.01), and RV outflow tract velocity time integral (r –0.49, P < 0.001). VVECMO was associated with higher RV subcostal strain (non-VVECMO –19.6 ± 6.7 vs. VVECMO –23.2 ± 7, P = 0.01) but not apical RV strain. On univariate analysis, RV subcostal strain was weakly associated with survival at 30 days (R 2 = 0.04, P = 0.05, odds ratio =1.08) while apical RV was not (P = 0.16). Conclusion  RV subcostal deformation imaging is a reliable surrogate for conventionally derived strain in critical care and may in time prove to be a useful diagnostic marker in this cohort. [ABSTRACT FROM AUTHOR]

Cardiac implanted electronic devices are commonplace in the modern practice of cardiology. This article reviews the history of the development of these technologies, with particular reference to the role played by UK physicians and members of the British Cardiovascular Society. Key breakthroughs in the treatment of heart block, ventricular arrhythmia and heart failure are presented in their historical and contemporary context so that the reader might look back on the incredible progress and achievements of the last 100 years and also look forward to what may be achieved in the coming decades. [ABSTRACT FROM AUTHOR]

Layer 2: Heart failure courses HFA exam The HFA exam is for professionals specializing in HF. Study material is the upcoming HFA Textbook of Heart Failure (Oxford University Press 2022), annual HFA congress, as well as the HFA guideline and consensus documents. Heart failure (HF) is a devastating chronic and disabling disease with a wide variety of pharmaceutical and device treatment options which are becoming increasingly complex to implement. HF specialists of tomorrow heart failure masterclass The HF specialists of tomorrow (HoT members) are the HF specialists in the early stages of their career (<40 years). [Extracted from the article]

Aims: Guidelines recommend the use of an implantable cardioverter‐defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) device based on the results of randomized controlled trials (RCTs), typically with selected patients and short follow‐up. Methods and results: We describe the 5 year survival rate and use of hospital services following ICD and CRT implantation in England from April 2011 to March 2013 using the national hospital administrative database covering emergency department visits, inpatient admissions, and clinic appointments, linked to the national death register. Five‐year survival was 64% after ICD implantation and 58% after CRT implantation, with median survival times of 6.8 and 6.2 years, respectively. Hospital use was high in both device groups, for the 5 years prior and after implantation, peaking around the implantation date. Most hospital activity was not primarily related to heart failure. Healthcare costs were dominated by admissions, but emergency department and clinic activity were both high. Only the CRT group saw total per‐patient costs fall after the index month (implantation), driven by a slight fall in the heart failure admission rate. Patients were typically older than in the trials, but with similar co‐morbidity except for substantially more atrial fibrillation and less dementia. Survival and device complications were similar to the RCTs. Conclusions: Clinical and cost‐effectiveness assessments of ICD and CRT implantation are supported by real‐world data, although the prevalence of atrial fibrillation remains substantially higher than in the RCTs. [ABSTRACT FROM AUTHOR]

Dr Dipak Kotecha, Professor of Cardiology from the Institute of Cardiovascular Sciences at the University of Birmingham, highlighted the various challenges and opportunities for using AI in daily practice, particularly for HF patients. B All correspondence relating to this paper should be sent to cardiopulse@unicatt.it b B Mark Nicholls reports from the ESC Digital Summit 2021. b Delegates to the online ESC Digital Summit 2021 heard that patients must be central to the digital healthcare revolution in cardiology, with a pivotal role in co-designing devices and shaping new therapeutic approaches and products. The role of wearables, artificial intelligence (AI), and the impact of digital health on heart failure (HF), atrial fibrillation (AF), and acute cardiovascular care were also key tracks. [Extracted from the article]

Copyright of Der Kardiologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background: Although there is trial evidence that complex interventions are effective for the self-management of heart failure, little evidence supports their effectiveness in routine practice. We used Social Practice Theory to guide a Type 1 Hybrid Trial: a mixed methods process evaluation of a complex intervention for heart failure. The objective of this paper is to explore the value of Social Practice Theory for implementation science.Methods: Social Practice Theory informed a mixed methods process evaluation of a multi-centre randomised controlled trial of a 12 week home-based intervention to optimise self-care support for people with heart failure and their caregivers - Rehabilitation EnAblement in Chronic Heart Failure (REACH-HF). Interviews were conducted with 19 people with heart failure and 17 caregivers at 4 months and 12 months after recruitment into the trial. Cases were constructed at the level of the individual, couple, facilitator and centre; and included multi-modal process and outcome data. Evaluative coding and subsequent within- and cross-case analyses enabled the development of a typology of relationships linking fidelity of intervention delivery and tailoring of content to individual needs and concerns. Social Practice Theory was used to interrogate the relationships between elements of the intervention and their implementation.Results: Of 216 trial participants, 107 were randomised to the intervention (REACH-HF plus usual care). The intervention was most effective when fidelity was high and delivery was tailored to the individual's needs, but less effective when both tailoring and fidelity were low. Theory-based analysis enabled us to model complex relationships between intervention elements (competencies, materials and meanings) and social context. The findings illustrate how intervention fidelity and tailoring are contextual and how the effectiveness of the REACH-HF intervention depended on both optimal alignment and implementation of these elements.Conclusion: The study demonstrates the utility of theory-based analysis which integrates data from multiple sources to highlight contexts and circumstances in which interventions work best. Social Practice Theory provides a framework for guiding and analysing the processes by which a complex intervention is evaluated in a clinical trial, and has the potential to guide context-specific implementation strategies for clinical practice.Trial Registration: ISRCTN, IISRCTN86234930 . Registered 13th November 2014. [ABSTRACT FROM AUTHOR]

This review aims to provide a comprehensive recapitulation of the evolution in the field of cardiac rhythm monitoring, shedding light in recent progress made in multilead ECG systems and wearable devices, with emphasis on the promising role of the artificial intelligence and computational techniques in the detection of cardiac abnormalities. [ABSTRACT FROM AUTHOR]

Background: Caregivers frequently provide support to people living with long-term conditions. However, there is paucity of evidence of interventions that support caregivers in their role. Rehabilitation EnAblement in Chronic Heart Failure (REACH-HF) is a novel home-based, health-professional-facilitated, self-management programme for patients with heart failure (HF) and their caregivers. Methods: Based on the random allocation of individual adult patients with reduced ejection fraction (HFrEF) and left ventricular ejection fraction <45% within the past five years, the caregiver of patients was allocated to receive the REACH-HF intervention over 12 weeks (REACH-HF group) or not (control group). Caregiver outcomes were generic health-related quality of life (EQ-5D-5L), Family Caregiver Quality of Life Scale questionnaire (FamQol), Caregiver Burden Questionnaire HF (CBQ-HF), Caregiver Contribution to Self-care of HF Index questionnaire (CC-SCHFI) and Hospital Anxiety and Depression Scale (HADS). Outcomes were compared between groups at 4, 6 and 12 months follow-up. Twenty caregivers receiving REACH-HF were purposively selected for qualitative interviews at 4 and 12 months. Results: Compared with controls (44 caregivers), the REACH-HF group (53 caregivers) had a higher mean CC-SCHFI confidence score at 12 months (57.5 vs 62.8, adjusted mean difference: 9.3, 95% confidence interval: 1.8–16.8, p = 0.016). No significant between group differences were seen in other caregiver outcomes. Qualitative interviews showed that most caregivers who received the REACH-HF intervention made positive changes to how they supported the HF patient they were caring for, and perceived that they had increased their confidence in the caregiver role over time. Conclusion: Provision of the REACH-HF intervention for caregivers of HF patients improved their confidence of self-management and was perceived for some to be helpful in supporting their caregiver role. [ABSTRACT FROM AUTHOR]

In recent years, wide ranging biomedical innovation has provided powerful new approaches for prevention, diagnosis and management of diseases. In order to translate such innovation into effective practice, physicians must frequently update their knowledge base and skills through continuing medical education and training. Medical Professional Societies, run as not-for-profit organizations led by peers, are uniquely placed to deliver balanced, disease oriented and patient centred education. The medical industry has a major role in the development of new, improved technology, devices and medication. In fact, the best innovations have been achieved through collaboration with scientists, clinical academics and practicing physicians. Industry has for many years been committed to ensure the optimal and safe application of its products by providing unrestricted support of medical education developed and delivered by international and national learned societies. Recently adopted Codes of Practice for the Pharmaceutical and Device industry were intended to enhance public trust in the relationship between biomedical industry and physicians. Unexpectedly, changes resulting from adoption of the Codes have limited the opportunity for unconditional industry support of balanced medical education in favour of a more direct involvement of industry in informing physicians about their products. We describe the need for continuing medical education in Cardiovascular Medicine in Europe, interaction between the medical profession and medical industry, and propose measures to safeguard the provision of high quality, balanced medical education. [ABSTRACT FROM AUTHOR]

The article informs that the organiser, the Zurich and. London Heart House decided to run the Cardiology Update 20 India as a fully online event, with shorter than usual talks over two afternoons on 19 and 20 September 2020.

Aim: Serelaxin is a recombinant human relaxin-2 hormone, which confers receptor-mediated vasodilatation in a tissue-specific fashion. The RELAX-AHF-EU study assessed the effect of serelaxin when added to standard-of-care (SoC) therapy on worsening heart failure (WHF)/all-cause death through Day 5 in patients hospitalised for acute heart failure (AHF) in Europe.Methods and Results: This multicentre, prospective, randomised, open-label, blinded-endpoint validation study enrolled hospitalised AHF patients and randomised (2:1) eligible patients (mild-to-moderate renal impairment and systolic blood pressure ≥ 125 mmHg) within 16 h of presentation with signs/symptoms of AHF, to receive 48 h intravenous infusion of 30 μg/kg/day serelaxin + SoC or SoC alone. The primary endpoint was adjudicated WHF/all-cause death through Day 5. Of 3183 patients targeted, 2666 were randomised when the study was terminated early by the sponsor due to the neutral results of the pivotal RELAX-AHF-2 study. Adjudicated WHF/all-cause death through Day 5 was significantly reduced in the serelaxin + SoC vs. SoC group (5.0% vs. 6.9%; hazard ratio 0.71; 95% confidence interval 0.51-0.98; P = 0.0172) (absolute risk reduction 1.9%, number needed to treat 53). The difference between treatment groups was not significant for WHF/all-cause death/heart failure rehospitalisation through Day 14 and length of hospital stay. A significantly smaller proportion of patients in the serelaxin + SoC vs. SoC group experienced persistent heart failure signs/symptoms at each visit until Day 4, or renal deterioration through Day 5 (all P ≤ 0.01). Overall incidence of treatment-emergent adverse events was comparable between treatment groups. Hypotension and decrease in haemoglobin/haematocrit were more frequent in the serelaxin + SoC group.Conclusion: When added to SoC, serelaxin reduced adjudicated WHF or all-cause death through Day 5 in AHF patients. The results from this open-label study should be considered in the context of the totality of the double-blind, randomised evidence on serelaxin in AHF. [ABSTRACT FROM AUTHOR]

Concentrations of total organic carbon (TOC), total petroleum hydrocarbons, polycyclic aromatic hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs) were determined in 84 near-surface soils (5–20cm depth) taken from a 255km2 area of Glasgow in the Clyde Basin, UK, during July 2011. Total petroleum hydrocarbon range was 79–2,505mgkg–1 (mean 388mgkg–1; median 272mgkg–1) of which the aromatic fraction was 13–74 % (mean 44 %, median 43 %) and saturates were 28–87 % (mean 56 %, median 57 %). ∑16 PAH varied from 2–653mgkg–1 (mean 32.4mgkg–1; median 12.5mgkg–1) and ∑31 PAH range was 2.47–852mgkg–1 (mean 45.4mgkg–1; median 19.0mgkg–1). ∑PCBtri-hepta range was 2.2–1052μgkg–1 (mean 32.4μgkg–1; median 12.7μgkg–1) and the ∑PCB7 range was 0.3–344μgkg–1 (mean 9.8μgkg–1; median 2.7μgkg–1). The concentration, distribution and source of the persistent organic pollutants were compared with those found in urban soils from other cities and to human health assessment criteria for chronic exposure to chemicals in soil. Total concentrations encountered were generally similar to other urban areas that had a similar industrial history. Benzo[ a ]pyrene concentrations were assessed against four different land use scenarios (irrespective of current land use) using generic assessment criteria resulting in six of 84 samples exceeding the residential criteria. Isomeric PAH ratios and relative abundance of perylene suggest multiple and environmentally modified pyrogenic PAH sources, inferred to be representative of diffuse pollution. ∑PCB7 concentrations were exceeded in 10 % of sites using the Dutch target value of 20μgkg–1. PCB congener profiles were environmentally attenuated and generally dominated by penta-, hexa- and hepta-chlorinated congeners. [ABSTRACT FROM AUTHOR]

The article presents a list of reviewer acknowledgement including Clause Abdallah, Julio Benitez and Stein Bergan.

This article provides an account of our group's efforts in developing aqueous-phase transfer hydrogenation reactions. It is comprised of mainly two parts. The first part concentrates on asymmetric transfer hydrogenation in water, enabled by Noyori-Ikariya catalysts, while the second part is concerned with the achiral version of the reaction catalysed by a new class of catalysts, iridacycles. A range of substrates are featured, including various carbonyl compounds and N-heterocycles. [ABSTRACT FROM AUTHOR]

Introduction: The Rehabilitation EnAblement in CHronic Heart Failure in patients with Heart Failure (HF) with preserved ejection fraction (REACH-HFpEF) pilot trial is part of a research programme designed to develop and evaluate a facilitated, home-based, selfhelp rehabilitation intervention to improve self-care and quality of life (QoL) in heart failure patients and their caregivers. We will assess the feasibility of a definitive trial of the REACH-HF intervention in patients with HFpEF and their caregivers. The impact of the REACHHF intervention on echocardiographic outcomes and bloodborne biomarkers will also be assessed. Methods and analysis: A single-centre parallel twogroup randomised controlled trial (RCT) with 1:1 individual allocation to the REACH-HF intervention plus usual care (intervention) or usual care alone (control) in 50 HFpEF patients and their caregivers. The REACHHF intervention comprises a REACH-HF manual with supplementary tools, delivered by trained facilitators over 12 weeks. A mixed methods approach will be used to assess estimation of recruitment and retention rates; fidelity of REACH-HF manual delivery; identification of barriers to participation and adherence to the intervention and study protocol; feasibility of data collection and outcome burden. We will assess the variance in study outcomes to inform a definitive study sample size and assess methods for the collection of resource use and intervention delivery cost data to develop the cost-effectiveness analyses framework for any future trial. Patient outcomes collected at baseline, 4 and 6 months include QoL, psychological well-being, exercise capacity, physical activity and HF-related hospitalisation. Caregiver outcomes will also be assessed, and a substudy will evaluate impact of the REACH-HF manual on resting global cardiovascular function and bloodborne biomarkers in HFpEF patients. Ethics and dissemination: The study is approved by the East of Scotland Research Ethics Service (Ref: 15/ES/0036). Findings will be disseminated via journals and presentations to clinicians, commissioners and service users. [ABSTRACT FROM AUTHOR]

The article focuses updates of the online version of the journal. It highlights the mission of the journal and the release of the first edition of the "ESC Textbook of Cardiovascular Medicine." It also mentions the decision of the board to launch the "European Society of Cardiology" to unveil a third edition of the textbook with completely different format.